Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer

Trial Profile

Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Docetaxel; Gemcitabine
  • Indications Bladder cancer; Renal cancer; Ureteral-neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 03 Jul 2018 Planned primary completion date changed from 1 May 2018 to 1 Dec 2018.
    • 05 Jun 2018 Results (n=20) from an expansion cohort, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top